ClinicalTrials.gov record
Terminated Phase 1 Interventional

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

ClinicalTrials.gov ID: NCT02538627

Public ClinicalTrials.gov record NCT02538627. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 11:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Multi Arm Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 With Seribantumab (MM-121), Istiratumab (MM-141), or Trametinib in Biomarker-selected Cancer Patients

Study identification

NCT ID
NCT02538627
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Merrimack Pharmaceuticals
Industry
Enrollment
5 participants

Conditions and interventions

Interventions

  • MM-121 Drug
  • MM-141 Drug
  • MM-151 Drug
  • trametinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2015
Primary completion
Oct 4, 2016
Completion
Oct 4, 2016
Last update posted
Sep 4, 2017

2015 – 2016

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
University of Colorado Aurora Colorado 80045
Northside Hospital Sandy Springs Georgia 30342
Northwestern Chicago Illinois 60611
Washington University St Louis Missouri 63110
Vanderbilt Nashville Tennessee 37235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02538627, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 4, 2017 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02538627 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →